| Description | Altenusin is a natural nonsteroidal fungal metabolite, as a novel selective agonist of FXR with an EC50 value of 3.2 ± 0.2 μM. |
| In vitro | Treatment of primary mouse hepatocytes with altenusin inhibited oleic acid–induced steatosis in vitro [1]. |
| In vivo | Administration of 2076A protected mice from high-fat diet (HFD)-induced obesity by reducing the body weight and fat mass by 22.9% and 50.0%, respectively. Administration of 2076A also decreased the blood glucose level from 178.3 ± 12.4 mg/dl to 116.2 ± 4.1 mg/dl and the serum insulin level from 1.4 ± 0.6 ng/dl to 0.4 ± 0.1 ng/dl[1]. |
| Target activity | FXR:EC50 : 3.2 ± 0.2 μM |
| molecular weight | 290.27 |
| Molecular formula | C15H14O6 |
| CAS | 31186-12-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (172.25 mM) |
| References | 1. Zheng Z, Zhao Z, Li S, et al. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor. Mol Pharmacol. 2017;92(4):425-436. doi:10.1124/mol.117.108829 |